AlphAIAlphAI — Financial news for AI agents
Stock TitanMAR 52 min read$OSPN

[Form 4] OneSpan Inc. Insider Trading Activity

OneSpan Inc. director Marc Zenner purchased 3,300 shares of the company's common stock in an open-market transaction at a price of $10.54 per share. This transaction increases his direct ownership to 83,208 OneSpan common shares. The filing was identified as a Form 4, indicating insider trading activity, and was noted to have a neutral impact and positive sentiment by Rhea-AI.

Original reporting
Stock Titan
Published Mar 5, 2026, 7:52 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Mar 5, 2026, 8:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$OSPN
Bullish
medium confidence
Mentioned
$OSPN
Relevance
6/10
AlphAI data visualization · based on Stock Titan
Decision brief

The 30-second read

$OSPNBullishMed
01

Why it matters

This insider activity suggests insider confidence, which may positively influence investor sentiment and stock performance.

02

Market read

While insider activity can be a positive signal, it should be integrated with other fundamental and technical analyses for comprehensive decision-making.

03

What to watch

Broader market conditions, recent earnings reports, and sector performance should be analyzed to validate the signal.

Relevance 6/10Timing: short-term (next 1-4 weeks)

Background

The filing indicates that Marc Zenner increased his holdings by purchasing 3,300 shares at $10.54, raising his direct ownership to 83,208 shares.

Company-level read

Ticker impact

$OSPNBullishMedium confidence
Context

Insider trading activity involving the company's director suggests increased insider confidence.

Expected impact

Moderate upward movement expected in the short term, contingent on broader market conditions.

Evidence & confidence

While insider buying can be a bullish indicator, it is one data point; broader market trends and company fundamentals should be considered.

Market effects

Sector

Potential positive sentiment in the financial technology sector, especially among companies with similar profiles.

Regional

Limited regional impact; primarily relevant to US markets.

Global

Minimal; insider activity is company-specific and unlikely to influence global markets.

Counterpoint

What could challenge this read

Insider buying could be motivated by personal reasons unrelated to company prospects; thus, it should not be solely relied upon for trading decisions.

Key entities

  • Person
    Marc Zenner

    Director of OneSpan Inc., involved in recent insider purchase.

  • Company
    OneSpan Inc.

    The subject of insider trading activity, operating in the digital identity and anti-fraud solutions sector.

Read at source← All news

Related articles

SEP 9
$OSPNMed

OneSpan’s (OSPN) Subscription Growth Masks A Shrinking Bottom Line

OneSpan (OSPN) reported Q2 2026 revenue of $60.5M, up 1% YoY. Subscription revenue grew 11% to $46.7M, while operating income fell 17% to $8.7M. The company raised full-year guidance, expecting $248M-$252M in revenue and $67M-$71M in Adjusted EBITDA. Net income declined to $6.8M, or $0.18 per share, from $8.3M a year earlier.

yahoo.com2 min
AUG 12
$OSPNMedAI 8/10

OneSpan (OSPN) Q2 2026 Earnings Call Transcript

OneSpan (OSPN) reported Q2 2026 revenue of $60.5 million, up 1% year over year, with subscription revenue at $46.7 million (+11%) and ARR of $189.7 million (+7%). Adjusted EBITDA was $16.9 million (28% margin). Full-year guidance raised to revenue $248-$252 million and adjusted EBITDA $67-$71 million. The company also launched DigipassONE and returned $2.9 million via repurchases.

fool.com6 min
AUG 4
$OSPNMed

OneSpan Reports Second Quarter 2026 Financial Results

OneSpan Inc. (OSPN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 OneSpan Reports Second Quarter 2026 Financial Results • Revenue increased 1% year-over-year to $60.5 million • Subscription revenue increased 11% year-over-year to $46.7 million • Operating income decreased 17% year-over-year to $8.7 million • Adjusted EBITDA decreas

SEC EDGAR 8-K7 min
OCT 24
$CLYMHighAI 8/10

Climb Bio reports early data on budoprutug for kidney diseases

Climb Bio (CLYM) presented Phase 2 trial data for budoprutug, an anti-CD19 antibody, showing B-cell depletion and PLA2R antibody reductions in kidney disease patients. The 200 mg dose achieved 70% mean antibody reduction, with 5/13 patients in remission. The 600 mg dose showed deeper B-cell depletion. The drug was well-tolerated. Climb Bio expects more data in 2027. Primary membranous nephropathy affects 75,000 people in the U.S. without FDA-approved treatments.

investing.com2 min